JOP20200110A1 - متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات - Google Patents

متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات

Info

Publication number
JOP20200110A1
JOP20200110A1 JOP/2020/0110A JOP20200110A JOP20200110A1 JO P20200110 A1 JOP20200110 A1 JO P20200110A1 JO P20200110 A JOP20200110 A JO P20200110A JO P20200110 A1 JOP20200110 A1 JO P20200110A1
Authority
JO
Jordan
Prior art keywords
series
antiviral compounds
novel
enantiomers
novel enantiomers
Prior art date
Application number
JOP/2020/0110A
Other languages
English (en)
Inventor
Gerald Kleymann
Christian Gege
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of JOP20200110A1 publication Critical patent/JOP20200110A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات جديدة مضادة للفيروسات ذات تكوين مجسم معين ، خاصةً مع متبلورات مضادة جديدة ، وعملية تحضيرها واستخدامها كأدوية ، خاصة كأدوية مضادة للفيروسات.
JOP/2020/0110A 2017-10-05 2018-10-04 متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات JOP20200110A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17195047 2017-10-05
PCT/EP2018/077022 WO2019068817A1 (en) 2017-10-05 2018-10-04 SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS

Publications (1)

Publication Number Publication Date
JOP20200110A1 true JOP20200110A1 (ar) 2020-05-07

Family

ID=60022026

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0110A JOP20200110A1 (ar) 2017-10-05 2018-10-04 متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات

Country Status (36)

Country Link
US (3) US11278534B2 (ar)
EP (2) EP4209491A1 (ar)
JP (1) JP7215689B2 (ar)
KR (1) KR102708082B1 (ar)
CN (1) CN111433203B (ar)
AR (1) AR113344A1 (ar)
AU (1) AU2018344471B2 (ar)
BR (1) BR112020006710A2 (ar)
CA (1) CA3077397A1 (ar)
CL (1) CL2020000869A1 (ar)
CR (1) CR20200154A (ar)
DK (1) DK3692039T3 (ar)
EA (1) EA202090620A1 (ar)
EC (1) ECSP20021132A (ar)
ES (1) ES2939652T3 (ar)
FI (1) FI3692039T3 (ar)
HR (1) HRP20230158T1 (ar)
HU (1) HUE061307T2 (ar)
IL (1) IL273681B1 (ar)
JO (1) JOP20200110A1 (ar)
LT (1) LT3692039T (ar)
MA (1) MA50609B1 (ar)
MD (1) MD3692039T2 (ar)
MX (1) MX2020003369A (ar)
NI (1) NI202000025A (ar)
PH (1) PH12020550132A1 (ar)
PL (1) PL3692039T3 (ar)
PT (1) PT3692039T (ar)
RS (1) RS64000B1 (ar)
SG (1) SG11202002420SA (ar)
SI (1) SI3692039T1 (ar)
TW (1) TWI706941B (ar)
UA (1) UA126163C2 (ar)
UY (1) UY37917A (ar)
WO (1) WO2019068817A1 (ar)
ZA (1) ZA202002150B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061307T2 (hu) * 2017-10-05 2023-06-28 Innovative Molecules Gmbh Szubsztituált tiazolok enantiomerei mint vírusellenes vegyületek
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN116783171A (zh) 2020-10-29 2023-09-19 创新分子股份有限公司 作为抗病毒化合物的氘化氨基噻唑化合物
IL314188A (en) 2022-01-17 2024-09-01 Innovative Molecules Gmbh Solid crystalline forms of helicase-primase inhibitors and a process for their preparation
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2024049760A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA984848A (en) 1970-01-16 1976-03-02 Kurt H. Pilgram Herbicides
SK89398A3 (en) 1995-12-29 1998-11-04 Boehringer Ingelheim Pharma Phenyl thiazole derivatives with anti herpes virus properties
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
ES2189404T3 (es) 1998-03-19 2003-07-01 Upjohn Co 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv.
US6500817B1 (en) 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
CA2412720A1 (en) 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129715A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
EP2101640B1 (en) 2006-12-08 2013-05-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Dry electrode cap for electro-encephalography
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
EP2635124A4 (en) * 2010-11-01 2014-04-16 Romark Lab Lc ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2573086A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
AU2017245679B2 (en) * 2016-04-06 2021-07-01 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
UY37496A (es) 2016-11-28 2018-06-29 Aicuris Anti Infective Cures Gmbh Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
HUE054845T2 (hu) 2016-11-28 2021-10-28 Aicuris Gmbh & Co Kg Az N-[5-(amino-szulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamid szabad bázis maleát sója, gyógyászati készítmények, elõállítási eljárások és Herpes vírusok kezelésére történõ alkalmazások
WO2018095576A1 (en) 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
JP7150343B2 (ja) 2017-01-09 2022-10-11 フェーノ・セラピューティクス・カンパニー・リミテッド チアゾール誘導体およびその使用
HUE061307T2 (hu) * 2017-10-05 2023-06-28 Innovative Molecules Gmbh Szubsztituált tiazolok enantiomerei mint vírusellenes vegyületek

Also Published As

Publication number Publication date
CN111433203A (zh) 2020-07-17
IL273681A (en) 2020-05-31
BR112020006710A2 (pt) 2022-11-08
IL273681B1 (en) 2024-09-01
ZA202002150B (en) 2022-10-26
PT3692039T (pt) 2023-03-07
ES2939652T3 (es) 2023-04-25
RS64000B1 (sr) 2023-03-31
CR20200154A (es) 2020-05-24
PH12020550132A1 (en) 2021-02-08
EP3692039A1 (en) 2020-08-12
EP3692039B1 (en) 2022-12-14
MX2020003369A (es) 2020-07-29
US20240316021A1 (en) 2024-09-26
EA202090620A1 (ru) 2020-07-10
AR113344A1 (es) 2020-04-22
AU2018344471A1 (en) 2020-04-09
DK3692039T3 (da) 2023-03-13
AU2018344471B2 (en) 2022-09-29
WO2019068817A1 (en) 2019-04-11
SG11202002420SA (en) 2020-04-29
ECSP20021132A (es) 2020-07-31
US20220152008A1 (en) 2022-05-19
KR20200066619A (ko) 2020-06-10
SI3692039T1 (sl) 2023-04-28
CN111433203B (zh) 2024-02-13
NI202000025A (es) 2020-07-31
JP7215689B2 (ja) 2023-01-31
KR102708082B1 (ko) 2024-09-19
LT3692039T (lt) 2023-03-27
JP2020536108A (ja) 2020-12-10
HRP20230158T1 (hr) 2023-03-31
MA50609A (fr) 2020-08-12
MA50609B1 (fr) 2023-03-31
FI3692039T3 (fi) 2023-03-23
MD3692039T2 (ro) 2023-05-31
US11278534B2 (en) 2022-03-22
UY37917A (es) 2019-04-30
PL3692039T3 (pl) 2023-04-17
TW201927758A (zh) 2019-07-16
EP4209491A1 (en) 2023-07-12
UA126163C2 (uk) 2022-08-25
CA3077397A1 (en) 2019-04-11
HUE061307T2 (hu) 2023-06-28
US20200289486A1 (en) 2020-09-17
TWI706941B (zh) 2020-10-11
CL2020000869A1 (es) 2020-09-21

Similar Documents

Publication Publication Date Title
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
ZA201708692B (en) Antibacterial compounds
PH12016501763A1 (en) Multispecific antibodies
MY190561A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12016500094A1 (en) Autotaxin inhibitors
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
IN2014MU00455A (ar)
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX350122B (es) Tinturas dispersas, su preparación y su uso.
MX2018007018A (es) Polimero de multiples etapas como aditivo de molienda y metodo de produccion del mismo.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MY180413A (en) Process for the decomposition of lignocellulose-containing biomass-material
MX2017000318A (es) Derivados del acido abscisico sustituido en 3'.
MX2019006956A (es) Proceso para la fabricacion de derivados de diazepina.
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.
WO2017059318A3 (en) Scaphopetalone analogs and their uses
PH12017501982A1 (en) Pharmaceutical compound